US Stock MarketDetailed Quotes
PALI Palisade Bio
- 3.5750
- -0.1250-3.38%
Close Aug 14 16:00 ET
- 3.5800
- +0.0050+0.14%
Post 19:26 ET
4.23MMarket Cap-192P/E (TTM)
3.7000High3.5600Low4.68KVolume3.6201Open3.7000Pre Close16.91KTurnover0.43%Turnover RatioLossP/E (Static)1.18MShares28.950052wk High0.43P/B3.85MFloat Cap3.300352wk Low--Dividend TTM1.08MShs Float594000.0000Historical High--Div YieldTTM3.78%Amplitude3.3000Historical Low3.6150Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Palisade Bio Stock Forum
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, has recently made a advancement in its drug development progr...
Palisade Bio, Inc.Thu, 11 July 2024 at 8:00 am GMT-4
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
Palisade Bio announced the successful completion of the first GMP manufacturing batch of its drug substance PALI-2108, targeted for treating moderate-to-severe ulcerative colitis (UC).
The company partnered with Eurofins for process development and scale-up. The drug substance has been utilized in completed murine and non-murine G...
now does that look nootropic AF or what?....
lol, I'm always noticing the Benzylpiperazine (BZP) structure within the skeleton. now that would be fun 😊
Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company dedicated to developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, has recently announced a milestone in its intellectual property portfolio. The Canadian Intellectual Property Office (CIPO) has issued a Notice of All...
NEWS
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
No comment yet